Q2 FY27 revenue up 32%, EBITDA doubles; Baddi target set

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹749.55

prior close

₹747.70

announcement price

In-mkt

timing

Nifty Microcap 250market+1.1%-1.8% vs market

Pharmaceuticals peers, median of 171sector+0.5%-1.2% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.4

15m

-0.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+1.1-1.8+0.5-1.2

Next day

-2.3pendingpending+0.4-2.7

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue was INR 1,342 crore, up 31.9% year on year, while EBITDA rose 106% to INR 195 crore and margin reached 14.5%. Profit after tax jumped 168.3% to INR 115 crore. CDMO revenue rose 38.6% to INR 1,115 crore. Management targets the new Baddi plant to deliver 10% to 15% of CDMO business in three years, received Zambia orders worth USD 25 million, and expects the loss-making API unit to reach breakeven within 3 to 4 quarters.

Likely market impact

Strong growth and higher margins support sentiment. Baddi and overseas contracts offer upside, while expansion execution and API losses remain risks.